Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030The Motley Fool • 12/16/24
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 12/10/24
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades StockBenzinga • 12/09/24
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program UpdateBusiness Wire • 12/08/24
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)Seeking Alpha • 11/19/24
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)Seeking Alpha • 11/15/24
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation OpportunityThe Motley Fool • 11/13/24
Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving AverageZacks Investment Research • 11/06/24
Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 11/06/24
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/06/24
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects ItSeeking Alpha • 11/05/24